Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L.
Berruti A, et al. Among authors: fazio n.
BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184.
BMC Cancer. 2014.
PMID: 24628963
Free PMC article.
Clinical Trial.